Calissendorff Swarting has represented Recipharm AB (publ) in its acquisition of a majority share stake in Indian CMO Nitin Lifesciences Ltd for a purchase price of INR 6,713 million (SEK 824 million)

Calissendorff Swarting has represented Recipharm AB (publ) in the acquisition of 74 per cent of the shares in Nitin Lifesciences Limited, an Indian family owned Contract Manufacturing Organisation (CMO) that produces sterile injectables, for a purchase price of INR 6,713 million (SEK 824 million) on a cash and debt free basis.

The acquisition was completed on 11 April 2016 following approval from the Indian Foreign Investment Board.